Ab­b­Vie staves off an­oth­er US Hu­mi­ra knock­off to 2023 as Eu­ro­pean launch looms

Just a few days be­fore Hu­mi­ra knock­offs are set to de­but in parts of Eu­rope, Ab­b­Vie has set­tled an­oth­er round of IP lit­i­ga­tion for its iron­clad mega-block­buster fran­chise in the US.

This time the deal is with San­doz, No­var­tis’ gener­ic arm, which has agreed to launch its biosim­i­lar in the US lat­er in 2023 than oth­er com­peti­tors will have, per their pre­vi­ous agree­ments with Ab­b­Vie.

Here’s what the suc­ces­sion of launch­es will look like:

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER